e-Therapeutics working to capitalise on AI "blindside" | News Direct

e-Therapeutics working to capitalise on AI "blindside"

e-Therapeutics PLC
News release by e-Therapeutics PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | May 04, 2023 08:20 AM Eastern Daylight Time

 

e-Therapeutics PLC (AIM:ETX OTCQX:ETXPF) CEO Ali Mortazavi speaks to Thomas Warner following the release of the computational biology and chemistry company's full year results for 2022. Mortazavi says that it was a "tricky year for the biotechnology sector as a whole" but that eTherapeutics has shown "remarkable resilience."

 

He goes on to highlight the opportunity being presented to the company by the advent of large language models (LLMs) and GPT-4, saying that he's never before seen a technology "blindside the world" to such an extent.

 

Contact Details

 

Proactive UK Ltd

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

AIComputational SciencesBiotechnologylarge language models